Form Type: 4

SEC EDGAR Link
Acccession Number:0000899243-19-016722
Date:2019-06-10
Issuer: AMEDISYS INC (AMED)
Original Submission Date:

Reporting Person:

KEMMERLY DAVID L
3854 AMERICAN WAY, SUITE A
BATON ROUGE, LA 70816

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-06-10 M 1,875 a $27.35 17,107 direct
COMMON STOCK 2019-06-10 M 3,125 a $27.35 20,232 direct
COMMON STOCK 2019-06-10 M 3,125 a $27.35 23,357 direct
COMMON STOCK 2019-06-10 S 8,125 d $117.77 15,232 direct
COMMON STOCK 0 $0.00 445 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 27.35 2019-06-10 deemed execution date M 1,875 (d) 2025-05-01 common stock 1,875 $27.35 0 direct
STOCK OPTION (RIGHT TO BUY) 27.35 2019-06-10 deemed execution date M 3,125 (d) 2025-05-01 common stock 3,125 $27.35 3,125 direct
STOCK OPTION (RIGHT TO BUY) 27.35 2019-06-10 deemed execution date M 3,125 (d) 2025-05-01 common stock 3,125 $27.35 6,250 direct
Footnotes
IDfootnote
f1 the total amount of shares beneficially owned includes 219 shares held in an employee stock purchase plan account.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $117.46 to $118.26, inclusive. the reporting person undertakes to provide to amedisys, inc. (the "issuer"), any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this form 4.
f3 the information in this report is based on a plan statement dated as of march 31, 2019.
f4 on may 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. the option vests based on the issuer's satisfaction of certain performance criteria for each of the fiscal years ending december 31, 2015, 2016, 2017 and 2018. the performance criteria for 2016 were met, resulting in vesting of the option as to 9,375 shares (the "2016 tranche options"), subject to additional time-based vesting as follows: one-third of the 2016 tranche options vested on may 1, 2017, one-third of the 2016 tranche options vested on may 1, 2018 and one-third of the 2016 tranche options vested on may 1, 2019. after the transaction being reported herein, the reporting person has exercised all of the 2016 tranche options.
f5 on may 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. the option vests based on the issuer's satisfaction of certain performance criteria for each of the fiscal years ending december 31, 2015, 2016, 2017 and 2018. the performance criteria for 2017 were met, resulting in vesting of the option as to 9,375 shares (the "2017 tranche options"), subject to additional time-based vesting as follows: one-third of the 2017 tranche options vested on may 1, 2018, one-third of the 2017 tranche options vested on may 1, 2019 and one-third of the 2017 tranche options will vest on may 1, 2020, assuming the reporting person remains continuously employed by the issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options. after the transaction being reported herein, the reporting person has exercised 6,250 of the 2017 tranche options.
f6 on may 1, 2015, the reporting person was granted an option to purchase 37,500 shares of common stock. the option vests based on the issuer's satisfaction of certain performance criteria for each of the fiscal years ending december 31, 2015, 2016, 2017 and 2018. the performance criteria for 2018 were met, resulting in vesting of the option as to 9,375 shares (the "2018 tranche options"), subject to additional time-based vesting as follows: one-third of the 2018 tranche options vested on may 1, 2019, and two-thirds of the 2018 tranche options will vest on may 1, 2020, assuming the reporting person remains continuously employed by the issuer on such date, subject to certain pro-rated vesting provisions as provided in the award agreement for the options. after the transaction being reported herein, the reporting person has exercised 3,125 of the 2018 tranche options.

Elevate your investments